Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nikhil Revankar

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Postgraduate Medicine|August 13, 2013
A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism preventionNikhil Revankar, John Patterson, Ananth Kadambi, et al.
Journal of Medical Economics|July 15, 2014
Modeling economic implications of alternative treatment strategies for acute bacterial skin and skin structure infectionsNikhil Revankar, Alexandra J Ward, Christopher G Pelligra, et al.
Pharmacoeconomics|August 16, 2014
Evaluating disease-modifying agents: a simulation framework for Alzheimer's diseaseShien Guo, Denis Getsios, Nikhil Revankar, et al.
Pharmacoeconomics|July 4, 2013
Smoking cessation treatment and outcomes patterns simulation: a new framework for evaluating the potential health and economic impact of smoking cessation interventionsDenis Getsios, Jenő P Marton, Nikhil Revankar, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Postgraduate Medicine|August 13, 2013
A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism preventionNikhil Revankar, John Patterson, Ananth Kadambi, et al.
Journal of Medical Economics|July 15, 2014
Modeling economic implications of alternative treatment strategies for acute bacterial skin and skin structure infectionsNikhil Revankar, Alexandra J Ward, Christopher G Pelligra, et al.
Pharmacoeconomics|August 16, 2014
Evaluating disease-modifying agents: a simulation framework for Alzheimer's diseaseShien Guo, Denis Getsios, Nikhil Revankar, et al.
Pharmacoeconomics|July 4, 2013
Smoking cessation treatment and outcomes patterns simulation: a new framework for evaluating the potential health and economic impact of smoking cessation interventionsDenis Getsios, Jenő P Marton, Nikhil Revankar, et al.
Pageof 1